BMS Opdivo+Yervoy combo received USFDA new indication approval.
Posted on15 Jul 2018
Comments0
Bristol-Myers Squibb Company announced that its Opdivo (nivolumab) 3 mg/kg plus low-dose Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) has received... Read More
What are the major differences between – Breakthrough Therapy Designation Vs. Fast Track Designation Vs. Priority Review Designation Vs. Accelerated Approval
Here is a quick comparison of the USFDA drug development expedited programs. This may help you to distinguishing all of them effectively. ... Read More